Conference Day Two

Thursday 27th February 2025

8:00 am Check in & Morning Coffee

8:50 am Chairperson’s Opening Remarks

Understanding Radiobiological Mechanisms of Killing & Immune Stimulation to Match Optimal Radiopharmaceutical Targets

9:00 am Understanding the Effects of Radiopharmaceuticals on Immune-Mediated Responses & Isotope Comparison on Anti-Tumor Immunity

  • Zachary Morris Chair and Paul Harari Professor of Human Oncology, University of Wisconsin-Madison

Synopsis

  • Comparing the immunologic effects of clinically-relevant radiopharmaceutical isotopes on anti-tumor immunity
  • Exploring poorly immunogenic tumors with intrinsic resistance to ICIs, combination with high LET, short-range alpha-emitters may prime adaptive CD8+ T cell recognition
  • Outlining acquired resistance to ICIs, low doses of low LET, longer range beta-emitting RPT may provide tumor inflammation and tumor cell susceptibility needed to renew clonal expansion of existing tumor-specific CD8+ T cells and generate immunologic memory

9:30 am Roundtables: Interrogating Radiopharmaceutical Mechanisms of Resistance to Build Strategies for Overcoming Them

Synopsis

  • Identifying molecular drivers of resistance such as alterations in DNA repair pathways, tumor microenvironment changes, and efflux transporters
  • Understanding how adaptive responses, such as changes in target expression or immune evasion, can lead to reduced effectiveness of radiopharmaceuticals
  • Explore innovative strategies to overcome resistance

10:00 am Exploring CAR-T & Radiopharmaceutical Combinations in Solid Tumors for Enhanced Efficacy

  • Quaovi Sodji Assistant Professor, University of Wisconsin-Madison

Synopsis

  • Appreciating that CAR T cells have shown limited effectiveness against solid tumors for various reasons
  • Outlining the increasing evidence of the immunostimulatory effects of radiopharmaceutical therapy,
  • Addressing some of the challenges faced by CAR T cell therapy especially in the metastatic setting

10:30 am Speed Networking & Morning Coffee Break

Rational Drug Design for Radiopharmaceuticals – Targeting Strategies

11:30 am Small Molecule Design, Strategy & Development for CAIX Targeting

  • Jonathan Young Chief Scientific Officer, WARF Therapeutics, Wisconsin Alumni Research Foundation

Synopsis

  • Exploring ligand engineering and design
  • Uncovering strategy behind small molecule development
  • Outlining selection of CAIX as a novel radiopharmaceutical target

12:00 pm Designing the Next Generation of Molecularly Targeted Radiotherapies (MTRs)

  • Alison Armour Founder Curadh pharmaceuticals, CURADH Pharmaceuticals

Synopsis

  • Addressing limitations with safety and efficacy in solid tumors
  • Tailoring next generation of MTRs for their PK/PD characteristics and tumour uptake
  • Considering treating a broader range of tumors for improved patient benefit through novel targets

12:30 pm Lunch Break & Networking

Rational Drug Design for Radiopharmaceuticals – Chelator & Linker Developments

1:30 pm Linker Design Trends & Implications for Enhanced Radiopharmaceutical Agents’ PD/PK

Synopsis

  • Covering the latest trends and innovations in linker design
  • Appreciating implications for radiopharmaceutical properties
  • Exploring strategies include plasma protein binding, covalent binding, charge and hydrophobicity, and enzymatic cleavage.

2:00 pm Advancing Chelator Technologies for Enhanced Radiopharmaceutical Development

Synopsis

  • Promoting altered drug properties
  • Outlining chelators of choice
  • Improving the pharmacokinetics and biodistribution of radiopharmaceuticals

2:30 pm Roundtables: Overcoming Kidney Toxicities for Small Molecular Size: Modifications for Radiopharmaceuticals

Synopsis

  • Exploring modifications to reduce kidney tox
  • Minimizing off-target effects
  • Utilizing reno protective agents

3:00 pm Afternoon Coffee Break & Networking

Exploring Radiation Absorption, Early Preclinical Dosimetry & Novel Assay Development

3:30 pm Roundtables: Future Thinking Predictive Modelling & Assays for Radiopharmaceuticals to Assess Translational Success

Synopsis

  • Exploring the application of machine learning algorithms to analyze complex datasets
  • Identify Patterns in Pharmacokinetics, biodistribution, and toxicity profiles, to develop robust predictive models that can forecast the translational success

4:15 pm Chair’s Closing Remarks

4:20 pm End of Conference Day Two